In two phase 3 , double-blind trials ( EXPEDITION 1 and EXPEDITION 2 ) , we randomly assigned 1012 and 1040 patients , respectively , with mild-to-moderate Alzheimer 's disease to receive placebo or solanezumab ( administered intravenously at a dose of 400 mg ) every 4 weeks for 18 months .